Noxopharm Limited

ASX:NOX.AX

0.06 (AUD) • At close April 19, 2024
Bedrijfsnaam Noxopharm Limited
Symbool NOX.AX
Munteenheid AUD
Prijs 0.06
Beurswaarde 17,534,280
Dividendpercentage 0%
52-weken bereik 0.033 - 0.165
Industrie Biotechnology
Sector Healthcare
CEO Dr. Gisela Mautner
Website https://www.noxopharm.com

An error occurred while fetching data.

Over Noxopharm Limited

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program

Vergelijkbare Aandelen

Antisense Therapeutics Limited logo

Antisense Therapeutics Limited

ANP.AX

0.058 AUD

Microba Life Sciences Limited logo

Microba Life Sciences Limited

MAP.AX

0.185 AUD

Orthocell Limited logo

Orthocell Limited

OCC.AX

0.395 AUD

Emyria Limited logo

Emyria Limited

EMD.AX

0.056 AUD

Cynata Therapeutics Limited logo

Cynata Therapeutics Limited

CYP.AX

0.21 AUD

MedAdvisor Limited logo

MedAdvisor Limited

MDR.AX

0.26 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)